二甲双胍在肿瘤免疫治疗中的研究进展

doi:10.3760/cma.j.cn371439-20220228-00054

摘要/Abstract

摘要：

近几十年来,免疫检查点抑制剂（ICI）开创了肿瘤治疗领域的新时代。尽管ICI疗效显著,但仍有较多患者无法从单独的免疫治疗中获益。联合治疗是目前国内外的主要研究方向。二甲双胍可以增强T细胞的数量及功能、影响巨噬细胞极化、促进自然杀伤细胞激活和调节免疫检查点表达等。大量的临床前和临床研究正在探索ICI与二甲双胍联合在不同肿瘤中应用的疗效和安全性。

关键词: 二甲双胍, 肿瘤, 免疫检查点抑制剂, PD-1, PD-L1

Abstract:

In recent decades, immune checkpoint inhibitors （ICIs） have ushered in a new era in oncology treatment. Despite the remarkable efficacy of ICIs, there are still many patients who do not benefit from immunotherapy alone. Combination therapy is currently the main research direction in China and abroad. Metformin can enhance the number and function of T cells, affect macrophage polarization, promote natural killer cell activation and regulate immune checkpoint expression. A large number of preclinical and clinical studies are exploring the efficacy and safety of ICIs in combination with metformin in different tumors.

Key words: Metformin, Neoplasms, Immune check inhibitors, PD-1, PD-L1

宁婷婷, 胡钦勇. 二甲双胍在肿瘤免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(5): 292-295.

Ning Tingting, Hu Qinyong. Research progress of metformin in tumor immunotherapy[J]. Journal of International Oncology, 2022, 49(5): 292-295.

参考文献 36

[1]	Kluger HM, Tawbi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce[J]. J Immunother Cancer, 2020, 8(1): e000398. DOI: 10.1136/jitc-2019-000398. doi: 10.1136/jitc-2019-000398
[2]	Tseng CH. The effect of metformin on male reproductive function and prostate: an updated review[J]. World J Mens Health, 2022, 40(1): 11-29. DOI: 10.5534/wjmh.210001. doi: 10.5534/wjmh.210001
[3]	Gabriel SS, Tsui C, Chisanga D, et al. Transforming growth factor-β-regulated mTOR activity preserves cellular metabolism to maintain long-term T cell responses in chronic infection[J]. Immunity, 2021, 54(8): 1698-1714.e5. DOI: 10.1016/j.immuni.2021.06.007. doi: 10.1016/j.immuni.2021.06.007 pmid: 34233154
[4]	Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion[J]. Nat Rev Immunol, 2015, 15(8): 486-499. DOI: 10.1038/nri3862. doi: 10.1038/nri3862 pmid: 26205583
[5]	Kim Y, Vagia E, Viveiros P, et al. Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC)[J]. Cancer Immunol Immunother, 2021, 70(4): 961-965. DOI: 10.1007/s00262-020-02703-8. doi: 10.1007/s00262-020-02703-8
[6]	Eikawa S, Nishida M, Mizukami S, et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin[J]. Proc Natl Acad Sci U S A, 2015, 112(6): 1809-1814. DOI: 10.1073/pnas.1417636112. doi: 10.1073/pnas.1417636112
[7]	Cha JH, Yang WH, Xia W, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1[J]. Mol Cell, 2018, 71(4): 606-620.e7. DOI: 10.1016/j.molcel.2018.07.030. doi: 10.1016/j.molcel.2018.07.030
[8]	Zhang Z, Li F, Tian Y, et al. Metformin enhances the antitumor activity of CD8⁺ T lymphocytes via the AMPK-miR-107-Eomes-PD-1 pathway[J]. J Immunol, 2020, 204(9): 2575-2588. DOI: 10.4049/jimmunol.1901213. doi: 10.4049/jimmunol.1901213 pmid: 32221038
[9]	Wang S, Lin Y, Xiong X, et al. Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase Ⅱ clinical trial[J]. Clin Cancer Res, 2020, 26(18): 4921-4932. DOI: 10.1158/1078-0432.CCR-20-0113. doi: 10.1158/1078-0432.CCR-20-0113
[10]	Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy[J]. Nat Biotechnol, 2020, 38(8): 947-953. DOI: 10.1038/s41587-020-0462-y. doi: 10.1038/s41587-020-0462-y pmid: 32361713
[11]	Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in cancer[J]. Trends Immunol, 2019, 40(4): 310-327. DOI: 10.1016/j.it.2019.02.003. doi: 10.1016/j.it.2019.02.003
[12]	Wang JC, Sun X, Ma Q, et al. Metformin's antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization[J]. J Cell Mol Med, 2018, 22(8): 3825-3836. DOI: 10.1111/jcmm.13655. doi: 10.1111/jcmm.13655
[13]	Uehara T, Eikawa S, Nishida M, et al. Metformin induces CD11b⁺-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects[J]. Int Immunol, 2019, 31(4): 187-198. DOI: 10.1093/intimm/dxy079. doi: 10.1093/intimm/dxy079
[14]	Liu Q, Tong D, Liu G, et al. Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration[J]. Clin Cancer Res, 2018, 24(22): 5622-5634. DOI: 10.1158/1078-0432.CCR-18-0420. doi: 10.1158/1078-0432.CCR-18-0420
[15]	Li K, Shi H, Zhang B, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer[J]. Signal Transduct Target Ther, 2021, 6(1): 362. DOI: 10.1038/s41392-021-00670-9. doi: 10.1038/s41392-021-00670-9
[16]	Qin G, Lian J, Huang L, et al. Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis[J]. Oncoimmunology, 2018, 7(7): e1442167. DOI: 10.1080/2162402X.2018.1442167. doi: 10.1080/2162402X.2018.1442167
[17]	Li L, Wang L, Li J, et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer[J]. Cancer Res, 2018, 78(7): 1779-1791. DOI: 10.1158/0008-5472.CAN-17-2460. doi: 10.1158/0008-5472.CAN-17-2460
[18]	Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The emergence of natural killer cells as a major target in cancer immunotherapy[J]. Trends Immunol, 2019, 40(2): 142-158. DOI: 10.1016/j.it.2018.12.003. doi: S1471-4906(18)30229-1 pmid: 30639050
[19]	Xia W, Qi X, Li M, et al. Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner[J]. Oncoimmuno-logy, 2021, 10(1): 1995999. DOI: 10.1080/2162402X.2021.1995999. doi: 10.1080/2162402X.2021.1995999
[20]	Xia C, He Z, Liang S, et al. Metformin combined with nelfinavir induces SIRT3/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice[J]. Eur J Pharmacol, 2019, 848: 62-69. DOI: 10.1016/j.ejphar.2019.01.045. doi: 10.1016/j.ejphar.2019.01.045
[21]	Liu T, Han C, Wang S, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy[J]. J Hematol Oncol, 2019, 12(1): 86. DOI: 10.1186/s13045-019-0770-1. doi: 10.1186/s13045-019-0770-1
[22]	Chen G, Yu C, Tang Z, et al. Metformin suppresses gastric cancer progression through calmodulin‑like protein 3 secreted from tumor‑associated fibroblasts[J]. Oncol Rep, 2019, 41(1): 405-414. DOI: 10.3892/or.2018.6783. doi: 10.3892/or.2018.6783
[23]	Shao S, Zhao L, An G, et al. Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer[J]. FASEB J, 2020, 34(8): 10860-10870. DOI: 10.1096/fj.202000951RR. doi: 10.1096/fj.202000951RR
[24]	Savic Prince S, Bubendorf L. Predictive potential and need for standardization of PD-L1 immunohistochemistry[J]. Virchows Arch, 2019, 474(4): 475-484. DOI: 10.1007/s00428-018-2445-7. doi: 10.1007/s00428-018-2445-7
[25]	Zhang JJ, Zhang QS, Li ZQ, et al. Metformin attenuates PD-L1 expression through activating Hippo signaling pathway in colorectal cancer cells[J]. Am J Transl Res, 2019, 11(11): 6965-6976.
[26]	Lu Y, Xin D, Guan L, et al. Metformin downregulates PD-L1 expression in esophageal squamous cell catrcinoma by inhibiting IL-6 signaling pathway[J]. Front Oncol, 2021, 11: 762523. DOI: 10.3389/fonc.2021.762523. doi: 10.3389/fonc.2021.762523
[27]	Chung YM, Khan PP, Wang H, et al. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8⁺ T cells via pharmacological activation of FOXO3[J]. J Immunother Cancer, 2021, 9(12): e002772. DOI: 10.1136/jitc-2021-002772. doi: 10.1136/jitc-2021-002772
[28]	Shen X, Zhao Y, Liu G, et al. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer[J]. Life Sci, 2020, 256: 117923. DOI: 10.1016/j.lfs.2020.117923. doi: 10.1016/j.lfs.2020.117923
[29]	Afzal MZ, Dragnev K, Sarwar T, et al. Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors[J]. Lung Cancer Manag, 2019, 8(2): LMT11. DOI: 10.2217/lmt-2018-0016. doi: 10.2217/lmt-2018-0016
[30]	Ciccarese C, Iacovelli R, Buti S, et al. Concurrent nivolumab and metformin in diabetic cancer patients: is it safe and more active?[J]. Anticancer Res, 2022, 42(3): 1487-1493. DOI: 10.21873/anticanres.15620. doi: 10.21873/anticanres.15620 pmid: 35220243
[31]	Yendamuri S, Barbi J, Pabla S, et al. Body mass index influences the salutary effects of metformin on survival after lobectomy for stage Ⅰ NSCLC[J]. J Thorac Oncol, 2019, 14(12): 2181-2187. DOI: 10.1016/j.jtho.2019.07.020. doi: S1556-0864(19)30650-1 pmid: 31398539
[32]	Afzal MZ, Mercado RR, Shirai K. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma[J]. J Immunother Cancer, 2018, 6(1): 64. DOI: 10.1186/s40425-018-0375-1. doi: 10.1186/s40425-018-0375-1
[33]	Pietras R, Xu H, Hu X, et al. P1.04-33 retrospective descriptive analysis of metformin with atezolizumab in advanced non-small cell lung cancer in the OAK trial[J]. J Thorac Oncol, 2018, 13(10): S538-S539. DOI: 10.1016/j.jtho.2018.08.748. doi: 10.1016/j.jtho.2018.08.748
[34]	王雪, 纪国欣, 纪超, 等. 二甲双胍对合并2型糖尿病的Ⅰ型子宫内膜癌患者预后的影响[J]. 国际肿瘤学杂志, 2020, 47(7): 404-408. DOI: 10.3760/cma.j.cn371439-20191125-00045. doi: 10.3760/cma.j.cn371439-20191125-00045
[35]	Yao X, Liu H, Xu H. The impact of metformin use with survival outcomes in urologic cancers: a systematic review and meta-analysis[J]. Biomed Res Int, 2021, 2021: 5311828. DOI: 10. 1155/2021/5311828. doi: 10. 1155/2021/5311828
[36]	Ugwueze CV, Ogamba OJ, Young EE, et al. Metformin: a possible option in cancer chemotherapy[J]. Anal Cell Pathol (Amst), 2020, 2020: 7180923. DOI: 10.1155/2020/7180923. doi: 10.1155/2020/7180923